Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Changhua site meets international regulatory standards for global medical applications
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Subscribe To Our Newsletter & Stay Updated
